Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10218305 | Health Policy and Technology | 2018 | 17 Pages |
Abstract
Findings indicate small price variation for pharmaceuticals that points towards the occurrence of price-convergence. The relatively minor association of EPR with pharmaceutical list prices could be explained by manufacturers' compensatory mechanisms including confidential price reductions and discounts while maintaining high list prices in countries with strong price-control measures or delayed product launch in countries with traditionally lower prices. Consequently, EPR cannot be directly associated with narrow European price corridor, and lower income countries still have slightly lower list prices.
Related Topics
Health Sciences
Medicine and Dentistry
Health Informatics
Authors
Marcell Csanádi, Zoltán Kaló, Christian P.J. Prins, Eszter Grélinger, Anna Menczelné Kiss, Frank-Ulrich Fricke, LeoÅ¡ Fuksa, Tomas Tesar, Manoela Manova, László Lorenzovici, Zoltán Vokó, Louis P. Garrison,